On Friday, in the course of current trade, Shares of Sprouts Farmers Market Inc (NASDAQ:SFM), dropped -0.16%, and is now trading at $ 27.54.
Sprouts Farmers Market, stated results for its 13-week first quarter ended March 29, 2015.
First Quarter Highlights:
- Net sales of $857.5 million; a 19% enhance from the same period in 2014
- Comparable store sales growth of 4.8% and two-year comparable store sales growth of 17.6%
- Net income of $37.5 million and diluted earnings per share of $0.24
- Adjusted net income of $38.6 million; a 9% enhance from the same period in 2014
- Adjusted diluted earnings per share of $0.25; a 9% enhance from the same period in 2014
- Adjusted EBITDA of $84.3 million; a 9% enhance from the same period in 2014
Sprouts Farmers Market, Inc. operates as a specialty retailer of fresh, natural, and organic food in the United States. The company’s stores offer fresh produce, bulk foods, vitamins and supplements, grocery products, meat and seafood products, deli and bakery products, dairy and dairy alternatives, frozen foods, beer and wine, natural health and body care products, and natural household products.
During an Afternoon trade, Shares of St. Jude Medical, Inc. (NYSE:STJ), dipped - 1.09%, and is now trading at $ 74.32.
St. Jude Medical, declared data from the ACCURATE Study shows that stimulation of the dorsal root ganglion (DRG) with the St. Jude Medical Axium Neurostimulator System is associated with superior pain relief over traditional spinal cord stimulation (SCS) for the treatment of chronic pain of the lower limbs.
The ACCURATE study, which is designed to support U.S. approval of DRG stimulation, represents the medical device industry’s largest study to date to evaluate patients suffering from chronic lower limb pain associated with complex regional pain syndrome (CRPS) or peripheral causalgia (nerve damage); two of the many chronic pain conditions presently underserved by traditional SCS therapy. Neuropathic pain represents one of the most prevalent yet under-treated chronic pain conditions presently facing U.S. patients. A total of 152 patients were enrolled in the trial at 22 centers across the United States.
St. Jude Medical, Inc., together with its auxiliaries, develops, manufactures and distributes cardiovascular medical devices for cardiac rhythm administration, cardiovascular, and atrial fibrillation therapy areas worldwide. It operates in two divisions, Implantable Electronic Systems, and Cardiovascular and Ablation Technologies.
Shares of Synergy Resources Corp (NYSEMKT:SYRG), during its Friday’s current trading session raised 0.25%, and is now trading at $ 12.17.
Synergy Resources Corp, declared that it successfully closed on the Sixth Amendment to its $500 million credit facility led by SunTrust Bank. The regular semi-annual redetermination provides for a borrowing base of $175 million. The facility currently bears interest at 2.5%, which is based upon LIBOR or Prime Rate plus a margin, with a floor interest rate of 2.5%.
Monty Jennings, CFO of Synergy Resources, commented, “Our borrowing base reflects the 25% growth of our proved reserves to over 40mm BOE as of February 28th, 2015 when compared to our fiscal year end reserves at August 31, 2014. We appreciate receiving unanimous approval of the $175 million borrowing base from the eight banks participating in the credit facility. Available borrowings under the facility and the $183 million of cash on our balance sheet as of May 31st, 2015 provides approximately $217 million in liquidity to Synergy as we develop our Wattenberg assets with horizontal drilling and as we expand our footprint in the Greater Wattenberg Area through leasing and acquisition activities.”
Synergy Resources Corporation engages in the acquisition, development, exploitation, exploration, and production of oil and natural gas properties primarily located in the Denver-Julesburg Basin in northeast Colorado. It holds interests in the Wattenberg field covering about 31,000 net developed and undeveloped acres located in Colorado; and Northern Extension area covering about 26,000 undeveloped acres.
Finally, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), lost - 1.69% Friday, hitting its highest level.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), declared long-term follow up from its pivotal Phase 2 trial of Iclusig (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study now shows that with a median follow-up of about 3.5 years for chronic phase CML (CP-CML) patients and a median follow-up of about 2.9 years in all patients in the trial, Iclusig continues to demonstrate anti-leukemic activity in patients with limited treatment options. Responses have been maintained long-term in CP-CML patients. Eighty-three percent (83%) of CP-CML patients who achieved a major cytogenetic response (MCyR) are estimated to remain in MCyR at three years.
Additionally, 95 percent of CP-CML patients who underwent ponatinib dose reductions maintained their responses (MCyR). Benefit-risk evaluations should guide the decision to initiate and maintain Iclusig therapy, particularly in patients who may be at raised risk for arterial occlusive events (AOE).
ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of medicines for cancer patients. The company offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, Europe, and other territories.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
